Back to Search
Start Over
Strategies for the treatment of HBV/HDV.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2018 Aug 15; Vol. 833, pp. 379-391. Date of Electronic Publication: 2018 Jun 21. - Publication Year :
- 2018
-
Abstract
- An estimated 240 million people worldwide are chronically infected with the hepatitis B virus (HBV). Despite readily available vaccination, HBV infections remain highly prevalent. As established HBV infections constitute a strong risk factor for developing hepatocellular carcinoma their treatment is a major task for the health system. Unfortunately, HBV is not curable with today's medicine. Approximately 15 million HBV patients have developed a hepatitis delta (HDV) infection on top of their HBV infection. The patients superinfected with this satellite virus suffer from a more severe disease development. The knowledge of the viruses, their classifications, clinical implications, treatment options and efforts to increase the drug variety are compiled in this review. The current standard therapies include nucleosidic reverse transcriptase inhibitors and interferon. As the known treatments fail to cure HBV and HDV, targeted treatment is highly warranted. The focus of this review is set on the drugs currently under clinical investigation. Furthermore, strategies for the development of targeted treatment, and compounds with novel mode of action are described.<br /> (Copyright © 2018. Published by Elsevier B.V.)
- Subjects :
- Antiviral Agents pharmacology
Antiviral Agents standards
Carcinoma, Hepatocellular epidemiology
Carcinoma, Hepatocellular prevention & control
Carcinoma, Hepatocellular virology
Clinical Trials as Topic
Hepatitis B virus drug effects
Hepatitis B, Chronic epidemiology
Hepatitis B, Chronic transmission
Hepatitis B, Chronic virology
Hepatitis D epidemiology
Hepatitis D transmission
Hepatitis D virology
Hepatitis Delta Virus drug effects
Hepatocytes virology
Humans
Liver Neoplasms epidemiology
Liver Neoplasms prevention & control
Liver Neoplasms virology
Practice Guidelines as Topic
Prevalence
Superinfection epidemiology
Superinfection virology
Treatment Outcome
Virus Replication drug effects
Antiviral Agents therapeutic use
Hepatitis B, Chronic drug therapy
Hepatitis D drug therapy
Superinfection drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 833
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 29935174
- Full Text :
- https://doi.org/10.1016/j.ejphar.2018.06.030